DESCRIPTION OF SHARED RESOURCE The Biostatistics Shared Resource (BSR) consists of partial effort from six PhD-level faculty biostatisticians and six MS-level or higher technical support staff to collaborate and consult with Kimmel Cancer Center investigators in the design, conduct, and analysis of cancer-related clinical, translational and scientific investigations, and to review clinical trial proposals for cancer-related studies within the Cancer Clinical Research Review Committee (CCRRC). The Division of Biostatistics consists of six PhD faculty, 2 PhD technical senior staff, and 4 MS-level staff, all participate at least partial effort to cancer research, but the Division also serves as the research resource for the entire University. The BSR provides consultation and expertise regarding study design (including validity of the overall design, feasibility of meeting objectives, sample size, study duration, and planned data analysis), recommendations for staffing (data management and analysis support), data analysis, preparation of reports and assistance with manuscript writing, and development of new biostatistical methods, when applicable. The general goal of the BSR is to ensure that study designs, monitoring, and analyses use state-of-the-art methods, and to help developmental studies supported by the Center successfully achieve peer reviewed funding. The BSR has experienced growth during the recent grant cycle, particularly by adding faculty and staff with mathematical programming and robust methods expertise. Plans for the future of Biostatistics include continued growth to meet the needs of the KCC, development in key areas including clinical trials design, and continued strength in methodological development that informs cancer research. The Biostatistics Shared Facility was used by 49 KCC members.

Public Health Relevance

Members of the Biostatistics Shared Resource (BSR) partner with cancer center investigators to design studies, write sections of grant applications related to study design and analysis techniques, participate in study planning and management meetings, complete data analysis, and write manuscripts for the scientific literature reporting findings. BSR faculty and staff have expertise in computational methods.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA056036-14
Application #
8517970
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-07-15
Project End
2018-05-31
Budget Start
2013-06-18
Budget End
2014-05-31
Support Year
14
Fiscal Year
2013
Total Cost
$196,124
Indirect Cost
$69,486
Name
Thomas Jefferson University
Department
Type
DUNS #
053284659
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Hussain, Maha; Daignault-Newton, Stephanie; Twardowski, Przemyslaw W et al. (2018) Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol 36:991-999
Shafi, Ayesha A; Schiewer, Matthew J; de Leeuw, Renée et al. (2018) Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. Eur Urol Oncol 1:325-337
Meyer, Sara E; Muench, David E; Rogers, Andrew M et al. (2018) miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential. J Exp Med 215:2115-2136
Mazina, Olga M; Mazin, Alexander V (2018) Reconstituting the 4-Strand DNA Strand Exchange. Methods Enzymol 600:285-305
Magee, Michael S; Abraham, Tara S; Baybutt, Trevor R et al. (2018) Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases. Cancer Immunol Res 6:509-516
Chervoneva, Inna; Freydin, Boris; Hyslop, Terry et al. (2018) Modeling qRT-PCR dynamics with application to cancer biomarker quantification. Stat Methods Med Res 27:2581-2595
Capparelli, Claudia; Purwin, Timothy J; Heilman, Shea A et al. (2018) ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma. Cancer Res 78:5680-5693
Nevler, Avinoam; Muller, Alexander J; Cozzitorto, Joseph A et al. (2018) A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2. J Am Coll Surg 226:596-603
Peng, Weidan; Furuuchi, Narumi; Aslanukova, Ludmila et al. (2018) Elevated HuR in Pancreas Promotes a Pancreatitis-Like Inflammatory Microenvironment That Facilitates Tumor Development. Mol Cell Biol 38:
Waldman, Scott A; Camilleri, Michael (2018) Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders. Gut 67:1543-1552

Showing the most recent 10 out of 807 publications